Media Coverage

Veterinary Medicine: Evaluation of Activated Charcoal

December 24, 2021

StarFish Medical Bio Services manager, Nick Allan, is a co-author of an original research article, Evaluation of Activated Charcoal as an Alternative to Antimicrobials for the Treatment of Neonatal Calf Diarrhea, published in the 24 December 2021 online edition of Veterinary Medicine: Research and Reports.

Neonatal calf diarrhea (NCD) is a major cause of death and economic loss in the cattle industry. Novel, non-antimicrobial therapies are needed to reduce antimicrobial use and optimize production efficiency. This production-level study compared the efficacy of activated charcoal to that of an antimicrobial regimen for treating mild-to-moderate cases of NCD, and identified the most common etiological agents.

Read the article here.


About Veterinary Medicine: Research and Reports

Veterinary Medicine: Research and Reports is an international, peer-reviewed, open access journal publishing original research, case reports, editorials, reviews and commentaries on all aspects of preclinical and clinical veterinary medicine. The journal is characterized by the rapid reporting of new and emerging diagnostic protocols and therapeutic strategies to overcome a wide range of veterinary diseases, as well as reporting the biological basis of these.

Editorial Staff

Professor Young S. Lyoo
[email protected]


About StarFish Medical

StarFish Medical provides award-winning design, development, commercialization, and flexible manufacturing outsourcing services —100% dedicated to the medical device and life science marketplace. StarFish Medical partners with innovative companies to create and manufacture breakthrough products for a full range of medical specialty areas including: Digital Health, Cardiovascular, Neurology, Urology, Gastroenterology, Otology, Ophthalmology, and In-Vitro Diagnostics.

StarFish Medical’s technical expertise includes electronics, mechanical, software/firmware systems engineering, in addition to industrial design and human factors. Regulatory Affairs (RA) and Quality Assurance (QA) consultants at StarFish Medical provide regulatory assistance for FDA, CE Mark and Health Canada submissions. Services include QA support for setting up QMS for start-up companies with implementation at the client’s site, and assisting with ISO 13485 certification audits.

For media inquiries:

Mike Camplin, VP, Marketing, StarFish Medical,  250.388.3537 x210  [email protected]

Related Link:

« All Media Coverage

Join over 6000 medical device professionals who receive our engineering, regulatory and commercialization insights and tips every month.